E

*click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Eculizumab 300mg concentrate for solution for infusion (Soliris®) SMC2236	Treatment of adults with refractory generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive.		177	Dec 2019
Eculizumab 300mg/30mL vial concentrate for solution for infusion (Soliris®) SMC 1130/16	In adults and children, for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.	Not available as not recommended for use in NHS Scotland	155	June 2016
Eculizumab (Soliris®) (915/13)	In children for treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH)	Not recommended	130	Sept/Oct 2013
Eculizumab (Soliris®) (767/12)	Atypical haemolytic uremic syndrome (aHUS)	Not available as not recommended for use in NHS Scotland	115 154	Mar/Apr 2012 May 2016
Eculizumab (Soliris®) (436/07)	Paroxysmal nocturnal haemoglobinuria (PNH)	Not recommended	100 75	Oct/Nov 2010 Dec 2007
Edoxaban (Lixiana®) (Venous thrombioembolism) (1090/15)	Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.	Non-formulary	152	Nov/Dec 2015
Edoxaban tosilate (Lixiana®) (Non- Valvular Atrial Fibrillation) (1095/15)	Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors	Non-formulary - pending local agreement	152	Nov/Dec 2015
Efalizumab (Raptiva®)	Moderate to severe plaque psoriasis	Discontinued	62 48	2005

Discontinued February 2009				
Efavirenz 50mg, 100mg and 200mg hard capsules and 600mg film-coated tablets (Sustiva®) SMC No. 1125/15	Antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected children aged 3 months to 3 years and weighing at least 3.5kg.	Formulary Hospital Use Only (Paediatrics/HIV clinic)	153	Jan/Feb 2016
Efavirenz, emtricitabine, tenofovir (Atripla®) (442/08)	HIV-1 infection	HOSPITAL ONLY (HIV Clinic)	79 78	May 2008 Apr 2008
Elbasvir 50 mg, grazoprevir 100mg film-coated tablet (Zepatier®) SMC No. 1203/17	Treatment of chronic hepatitis C (CHC) in adults. (The efficacy of elbasvir-grazoprevir has not been demonstrated in genotypes 2, 3, 5 and 6. Elbasvir-grazoprevir is not recommended in patients infected with these genotypes).	Available in line with National Guidance Hospital Use only Hep C Clinic	159 160	Feb 2017 Apr 2017
efgartigimod alfa concentrate for solution for infusion (Vyvgart®) SMC2561	as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.	Not available as not recommended for use in NHS Scotland	195	December 2023
Eflornithine cream (Vaniqa®)	Facial hirsutism in women	Non-formulary	53 50	2005
Eladocagene exuparvovec (Upstaza) SMC2586	for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype.	Available in line with national guidance	195	December 2023
Eliglustat 84mg hard capsules (Cerdelga®) SMC No 1277/17	For the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 poor metabolisers, intermediate metabolisers or extensive metabolisers		166	Feb 2018
Elosulfase alfa (Vimizim®) (1072/15)	For the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.	Not recommended	151	Sep/Oct 2015
Elotuzumab 300mg and 400mg powder for concentrate for	Treatment of multiple myeloma in combination with lealidomide and dexamethasone in adult patient who have received at least	Not available as not recommended for use in NHS	156	Sep 2016

solution for infusion (Empliciti®)	one prior therapy.	Scotland		
Elranatamab solution for injection (Elrexfio®) SMC2669	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Available in line with national guidance		
Eltrombopag film-coated tablets 25mg and 50mg (Revolade®) (1206/17)	Chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to 17 years who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). SMC Restriction: use in patients with severe symptomatic ITP or a high risk of bleeding.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts – decision expected by April 2017	159	Feb 2017
Eltrombopag (Revolade®) (919/13)	Chronic hepatitis C virus infection,	HOSPITAL ONLY (Hepatitis Clinic)	133	Dec 13/Jan 14
Eltrombopag (Revolade®) (625/10)	Chronic immune (idiopathic) thrombocytopenic purpura (ITP)	Non-formulary - pending protocol	116 99	Apr/May 2012 Aug/Sept 2010
Eluxadoline, 75mg and 100mg film-coated tablets (Truberzi®) SMC No 1292/18	In adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).	Not available as not recommended for use in NHS Scotland	167	April 2018
Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide film-coated tablet 90 mg / 90 mg / 120 mg / 6 mg (Genvoya®) SMC2809	Treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in paediatric patients aged from 2 years and with body weight at least 14 kg to less than 25 kg.	Not available as not recommended for use in NHS Scotland		
Elvitegravir 150mg / cobicistat 150mg / emtricitabine 200mg / tenofovir alafenamide 10mg (Genvoya ®) SMC No 1323/18	Treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in children aged from 6 years and with body weight	Not available as not recommended in NHS Scotland	168	May 2018

	at least 25 kg for whom alternative regimens are unsuitable due to toxicities.			
Elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir disoproxil (as fumarate) 245mg film-coated tablets (Stribild ®) SMC No 1310/18	Treatment of HIV-1 infection in adolescents aged 12 to <18 years weighing ≥35kg who are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild® and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate	Not available as not recommended for use in NHS Scotland	167	April 2018
Elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg, tenofovir alafenamide 10mg film coated tablet (Genvoya®) (1142/16)	The treatment of adults and adolescents (aged 12 year and older with body weight at least 35kg) infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class emtricabine or tenofovir	Available in line with National Guidance	155	June 2016
Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil (as fumarate) (Stribild®) (887/13)	HIV-1	HOSPITAL ONLY (HIV Clinic)	131 129	Oct/Nov 2013 Aug/Sept 2013
Empagliflozin film-coated tablets (Jardiance®) SMC2642	In patients having individually optimised standard care (including angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, unless these are contraindicated or not tolerated), and either, at the start of treatment: • an estimated glomerular filtration rate (eGFR) of 20 mL/min/1.73m2 up to 45 mL/min/1.73m2, or • an eGFR of 45 mL/min/1.73m2 up to 90 mL/min/1.73m2 and either:A urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more, orType 2 Diabetes Mellitus (T2DM).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	198 not yet published	
Empagliflozin 10mg film-coated	in adults for the treatment of symptomatic chronic heart failure	Not routinely available as local clinical experts do not wish to	187	Dec 2021

tablets (Jardiance®) SMC2396	with reduced ejection fraction. Empagliflozin offers an additional treatment choice in the therapeutic class of sodium glucose co-transporter 2 inhibitors in this indication.	add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Empagliflozin plus linagliptin 10mg/5mg, 25mg/5mg film-coated tablets (Glyxambi®) SMC1236/17	In adults aged 18 years and older with type 2 diabetes mellitus: • To improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi® do not provide adequate glycaemic control • When already being treated with the free combination of empagliflozin and linagliptin SMC restriction: Restricted to use in line with the previous SMC advice on empagliflozin and linagliptin.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	176	Oct 2019
Empagliflozin plus metformin (Synjardy®) (1092/15)	For use in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:	Non-formulary - absence of clinician demand	152	Nov/Dec 2015
Empagliflozin (Jardiance®) (993/14)	Type 2 diabetes	Non-formulary - absence of clinician demand	142	Oct/Nov 2014
Empagliflozin film-coated tablet (Jardiance®) SMC2523	In adults for the treatment of symptomatic chronic heart failure with preserved ejection fraction (left ventricular ejection fraction [LVEF] >40%).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	193	
Emtricitabine / tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada®) SMC No. (1263/17)	Treatment of HIV-1 infected adolescents aged 12 to <18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first line agents.	Not available as not recommended for use in NHS Scotland	163	Sep 2017
Emtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada®) (1225/17)	In combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.	Available in line with national guidance	161	Jun 2017

Emtricitabine/tenofovir alafenamide 200mg/25mg, 200mg/10mg film coated (Descovy®)	In combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1	Available in line with national guidance	156	Sep 2016
Emtricitabine (Eviplera®) (951/14)	HIV-1	HOSPITAL ONLY (HIV Clinic)	137	Apr/May 2014
Emtricitabine (Eviplera®) (759/12)	HIV-1	HOSPITAL ONLY (HIV Clinic)	115	Mar/Apr 2012
Emtricitabine (Emtriva®)	HIV	HOSPITAL ONLY	55 42	2006 2004
Emtricitabine/tenofovir (Truvada®)	HIV	HOSPITAL ONLY	55	2006
Encorafenib (Braftovi) SMC2312	In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy. Treatment with encorafenib plus cetuximab was associated with an improvement in overall survival when compared with investigator's choice of cetuximab plus differing chemotherapy in BRAF V600E mutated patients who had received first and second-line therapies for metastatic CRC.	Available in line with national guidance	185	July 2021
Encorafenib 50mg and 75mg hard capsules (Braftovi®) SMC2238	In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	Available in line with local guidance for prescribing	179	Apr 2020
Encorafenib 50mg and 75mg hard capsules (Braftovi®)	In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a	Not available as not recommended for use in	176	Oct 2019

SMC2145	BRAF V600 mutation.	NHS Scotland.		
Enfluvirtide (Fuzeon®)	HIV	Restricted use	29	2003
enfortumab vedotin 20mg and 30mg powder for concentrate for solution for infusion (Padcev®) SMC2505	As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor.	Not available as not recommended for use in NHS Scotland	190	August 2022
Enoxaparin (Clexane®) (380/07)	Acute STEMI	Not recommended	91	July 2009
Entacavir (Baraclude®) (1049/15)	For the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to 18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis.	Hospital Use Only (Under direction of Liver team at Aberdeen's children's hospital & King's college hospital London)	148	May 2015
Entecavir (Baraclude®) (747/11)	Chronic hepatitis B (CHB) - decompensated liver disease Chronic hepatitis B (CHB) - compensated liver disease	Not recommended HOSPITAL ONLY	114 62	Feb 2012 2006
Entrectinib 100mg and 200mg hard capsules (Rozlytrek®) SMC2295	As monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, • who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and • who have not received a prior NTRK inhibitor • who have no satisfactory treatment options	Not routinely available as local clinical experts do not wish to add the medicines to the formulary at this time.	184	May 2021

	In a pooled analysis of three phase I/II studies in adults with metastatic or locally advanced NTRK fusion-positive solid tumours, 64% of patients achieved an objective response with entrectinib treatment. The median duration of response in these patients was 12.9 months. Positive objective response rate results were also reported in a phase I/Ib paediatric study.			
Entrectinib 100mg and 200mg hard capsules (Rozlytrek®) SMC2294	As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.	Available in line with national guidance	183	March 2021
Enzalutamide 40mg film-coated tablets (Xtandi®) SMC2400	treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). Enzalutamide improved radiographic progression-free survival compared with placebo and it improved overall survival compared with placebo and an older non-steroidal anti-androgen (NSAA) in adults with mHSPC who were receiving ADT.	Available in line with national guidance	188	April 2022
Enzalutamide 40mg soft capsules (Xtandi®) SMC2195	The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC).		177	Dec 2019
Enzalutamide (Xtandi®) (1066/15)	Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.	Available in line with national guidance Hospital only Oncology	150 151 154	July 2015 Sep/Oct 2015 May 2016
Enzalutamide (Xtandi®) (911/13)	Treatment of adult men with mCRPC	HOSPITAL ONLY (Oncology)	132	Nov/Dec 2013
Epcoritamab concentrate for solution for injection and solution for injection (Tepkinly®) SMC2632	Monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.	Available in line with national guidance	198 not yet published	

Epinastine eye drops (Relestal®)	Seasonal allergic conjunctivitis	Not recommended	58	2006
Eplerenone (Inspra®)(793/12)	NYHA Class II (chronic) heart failure	GPs may prescribe under the direction of Cardiology/Heart Failure Clinic or the Heart Failure Nurses Liaison Services.	119	Aug/Sept 2012
Eplerenone (Inspra®)	Heart failure post-MI	Locally recommended under the direction of a Cardiologist	77 (Update) 50 47	Mar 2008 2005 2004
eplontersen solution for injection in pre-filled pen (Wainzua®) SMC2755	for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy. Eplontersen offers an additional treatment choice of transthyretin (TTR) gene silencer for this indication. Another TTR gene silencer was accepted for use under the ultra-orphan process.			
Epoetin alfa 2,000 / 4,000 / 10,000 / 40,000 international units per mL solution for injection in pre-filled syringe (Eprex®) SMC2164	Treatment of symptomatic anaemia (haemoglobin concentration of ≤10g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (<200 mU/mL).	Not available as not recommended for use in NHS Scotland	174	May 2019
Epoetin theta (Eporatio®)	Symptomatic anaemia associated with chronic renal failure	HOSPITAL ONLY	97	June/Jul 2010
Epoetin alfa (Binocrit®) (597/10)	Symptomatic anaemia associated with chronic renal failure	Non-formulary	95	Feb/Mar 2010
Epoetin zeta (Retacrit®) (467/08)	Anaemia in patients with chronic renal failure	Not recommended	80	June 2008

Epoetin delta (Dynepo®) WITHDRAWN - CLICK HERE for EMA statement	Anaemia	Withdrawn	74	Nov 2007
Eptinezumab 100mg concentrate for solution for infusion (Vyepti®) SMC2547	Indication under review: for the prophylaxis of migraine in adults who have at least 4 migraine days per month. SMC restriction: for patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments. Eptinezumab provides an additional treatment choice in the therapeutic class of calcitonin gene-related peptide (CGRP) inhibitors.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	192	April 2023
Erdafitinib film-coated tablets (Balversa®) SMC2738	As monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. In a phase III study of patients with metastatic UC and fibroblast growth factor receptor (FGFR) alterations who had progression after one or two previous treatments that included a programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, erdafitinib significantly improved overall survival compared with investigators choice of single agent chemotherapy.			
Erdosteine (Erdotin®)	Acute exacerbations of chronic bronchitis	Not recommended	74	Nov 2007
Erenumab 70mg solution for injection in pre-filled pen (Aimovig®) SMC2134	For the prophylaxis of migraine in adults who have at least four migraine days per month. SMC restriction: patients with chronic migraine who have at least four migraine days per month and for whom at least three prior prophylactic treatments	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or	174	May 2019

	have failed	there is a local preference for alternative medicines		
Eribulin 0.44mg/mL solution for injection (Halaven®) SMC2231	Treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.		177	Dec 2019
Eribulin (mesilate) (Halaven®)(1065/15)	For the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.	Available in line with national guidance Hospital only Oncology	150 151 154	July 2015 Sep/Oct 2015 May 2016
Eribulin (Halaven®) (726/11)	Metastatic breast cancer	Not recommended	111	Nov 2011
Erlotinib (Tarceva®) (382/07)	Metastatic pancreatic cancer	Not recommended	71	July 2007
Erlotinib (Tarceva®) (749/11)	Non small cell lung cancer	HOSPITAL ONLY (Oncology)	119 116 114 108 Protocol 102 59 55	Aug/Sept 2012 Apr/May 2012 Feb 2012 Aug 2011 Jan/Feb 2011 2006
Ertapenem (Invanz®)	Prophylaxis of colorectal surgical site infection	Not recommended	74 (Update) 73	Nov 2007 Oct 2007
Ertapenem (Invanz®)	Intra-abdominal infection - children/adolescents	HOSPITAL ONLY	62 (Update) 60	2006
Ertapenem (Invanz®)	Intra-abdominal infection - adults	HOSPITAL ONLY	47	2004
Ertapenem (Invanz®)	Diabetic foot infections		65	Jan 2007
Etranacogene dezaparvovec concentrate for solution for	for the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a	Available from a specialist	198	NYP

infusion (Hemgenix®) SMC2649	history of factor IX inhibitors.	centre in another Board		
Ertugliflozin 5mg, 15mg film-coated tablet (Steglatro®) SMC2102	In adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: • As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. • In addition to other medicinal products for the treatment of diabetes. SMC restriction: ertugliflozin is accepted for use as monotherapy and as add-on therapy. When used as monotherapy it is restricted to patients who would otherwise receive a dipeptidyl peptidase-4 inhibitor and in whom a sulphonylurea or pioglitazone is not appropriate	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	173	March 2019
Escitalopram (Cipralex®) (406/07)	Obsessive compulsive disorder	Not recommended	73	Nov 2007
Escitalopram (Cipralex®)	Major depressive episodes or generalised anxiety disorder	GPs may prescribe under the direction of a psychiatrist (Mental Health specialist list)	25	2003
Escitalopram (Cipralex®) (475/08)	Social anxiety disorder	Not recommended	79	May 2008
Esketamine 28mg nasal spray, solution (Spravato®) SMC2539	Co-administered with oral antidepressant therapy, in adults with a moderate to severe episode of Major Depressive Disorder, as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency.	Not available as not recommended for use in NHS Scotland	191	Nov 2022
Esketamine 28mg nasal spray, solution (Spravato®) SMC2258	In combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments	Not currently available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for	181	November 2020

	with antidepressants in the current moderate to severe depressive episode. In a phase III study in adults (aged 18 to 64 years) with treatment resistant depression, esketamine plus newly initiated antidepressant significantly reduced the Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to week 4 compared with placebo plus newly initiated antidepressant. A significantly lower rate of relapse in patients who received esketamine plus antidepressant over placebo plus antidepressant was demonstrated in a further phase III study.	alternative medicines		
Eslicarbazepine acetate 200mg and 800mg tablets and oral suspension 50mg/mL (Zebinix®) SMC2087	As adjunctive therapy in adolescents and children aged above 6 years with partial-onset seizures with or without secondary generalisation. SMC restriction: patients with highly refractory epilepsy who have been heavily pre-treated and remain uncontrolled with existing anti-epileptic drugs.	Available in line with national guidance	174	May 2019
Eslicarbazepine acetate 200mg and 800mg tablets (Zebinix ®) SMC2090	As monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy	Not routinely available as not recommended for use in NHS Scotland	169	July 2018
Eslicarbazepine (Zebinix®) (592/09)	Adults with partial-onset seizures with or without secondary generalisation	GPs may prescribe under the direction of Neurology/ Epilepsy Clinic	103 100 94	Feb/Mar 2011 Oct/Nov 2010 Dec 09/Jan 10
Esomeprazole (Nexium®) (422/07)	Zollinger-Ellison Syndrome	May be prescribed under the direction of the GI Clinic	75	Dec 2007
Esomeprazole (Nexium®) (693/10)	GORD in patients 1-11 years	Non-formulary	100 99	Oct/Nov 2010 Aug/Sept 2010
Esomeprazole (Nexium®)	GORD in patients 12-17 years	GPs may prescribe under the direction of the GI Clinic	69	June 2007

Esomeprazole (Nexium® IV) (578/09)	Prevention of re-bleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers	HOSPITAL ONLY	96 93	Apr/May 2010 Oct/Nov 2009
Esomeprazole (Nexium® IV)	Gastroesophageal reflux disease	Not recommended	45	2004
Esomeprazole (Nexium®)	Healing of NSAID associated gastric ulcers	Not recommended	59	2006
Esomeprazole (Nexium®)	Prevention of NSAID gastric/duodenal ulcers	Not recommended	59	2006
Estetrol 14.2mg / drospirenone 3mg film-coated tablets (Drovelis®) SMC2564	Oral contraception.	Not available as not recommended for use in NHS Scotland		
Estradiol 1mg / micronised progesterone 100mg capsules (Bijuve®) SMC2502	Continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses. The experience in treating women older than 65 years is limited. Estradiol / micronised progesterone (Bijuve®) offers an additional treatment choice of continuous combined hormone replacement therapy.	Available in line with local guidance for prescribing	191	Nov 2022
Estradiol/drospirenone (Qlaira®) (583/09)	Oral contraception	Not recommended	93	Oct/Nov 2009
Estradiol/drospirenone (Angeliq®)	Prevention of postmenopausal osteoporosis	Not recommended	55	2006
Estradiol/drospirenone (Angeliq®)	Prevention of menopausal symptoms	Not recommended	55	2006
Estradiol/levenorgestrel transdermal patch (FemSeven Sequi®)	HRT		23	2002
Estradiol/levenorgestrol transdermal patch (FemSeven	HRT		24	2003

Conti®)				
Etanercept (Enbrel®) (842/13)	Treatment of polyarthritis (rheumatoid factor positive or negative): psoriatic arthritis; and enthesitis-related arthritis	HOSPITAL ONLY (Paediatric Rheumatology Clinic)	125	Mar/Apr 2013
Etanercept (Enbrel®) (782/12)	Active polyarticular juvenile idiopathic arthritis in children and adolescents	HOSPITAL ONLY (Paediatric Rheumatology Clinic)	117	May/June 2012
Etanercept (Enbrel®) (781/12)	Chronic severe plaque psoriasis in children and adolescents	HOSPITAL ONLY (Dermatology Clinic)	117 93 92	May/June 2012 Oct/Nov 2009 Aug/Sept 2009
Etanercept (Enbrel®)	Rheumatoid arthritis	HOSPITAL ONLY	61	2006
Etanercept (Enbrel®)	Ankylosing spondylitis	HOSPITAL ONLY (Rheumatology Clinic)	62 54	2006 2005
Etanercept (Enbrel®)	Psoriatic arthritis	HOSPITAL ONLY	42 Protocol	2004
Etelcalcetide 2.5mg, 5mg, and 10mg solution for injection (Parsabiv®) SMC No. (1262/17)	Treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy	Not available as not recommended for use in NHS Scotland	164	Oct 2017
Ethinylestradiol (Geradel®) (643/10)	Oral contraception	Formulary - 2nd line choice	100	Oct/Nov 2010
Ethinylestradiol (Millinette®) (644/10)	Oral contraception	Formulary - 2nd line choice	100	Oct/Nov 2010
Ethinylestradiol (Rigevidon®) (646/10)	Oral contraception	Formulary - 1st line choice	100	Oct/Nov 2010
Ethinylestradiol (TriRegol®) (645/10)	Oral contraception	Non-formulary	100	Oct/Nov 2010

Etomidate-Lipuro®	Induction of general anaesthesia		47	2004
Etonogestrel/ethinylestradiol (NuvaRing®) (502/08)	Contraception	Non-formulary	94 93 86	Dec 09/Jan 10 Oct/Nov 2009 Jan 2009
Etonogestrel implant Nexplanon®) (655/10)	Contraception	Formulary	101	Dec 10/Jan 2011
Etoricoxib (Arcoxia®)(847/12)	Short-term treatment of moderate pain associated with dental surgery	Not recommended	124	Feb 2013
Etoricoxib (Arcoxia®)(576/09)	Ankylosing spondylitis	Not recommended	92	Aug/Sept 2009
Etoricoxib (Arcoxia®)	OA, RA, gout	Non-formulary	62 25	2006 2003
Etrasimod film-coated tablets (Velsipity®) SMC2655	Treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	198 not yet published	
Etravirine (Intelence®) (901/13)	HIV-1	HOSPITAL ONLY Paediatrics under supervision of HIV specialists in Glasgow and Edinburgh	130	Sept/Oct 2013
Etravirine (Intelence®)	HIV-1 infected adults in combination with a boosted protease inhibitor and other antiretroviral products	HOSPITAL ONLY (HIV Clinic)	95 92 86	Feb/Mar 2010 Aug/Sep 09 Jan 2009
Evolocumab 140mg solution for injection in pre-filled syringe /	In adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial	Not available as not recommended for use in NHS	172	Dec 2018

140mg solution for injection in pre-filled pen / 420mg solution of injection in cartridge (Repatha®) SMC2133	disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: • in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.	Scotland Note that SMC advice (1148/16) still stands		
Everolimus 2mg, 3mg and 5mg dispersible tablets (Votubia®) SMC No 1331/18	Adjunctive treatment of patients aged two years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC).	Available in line with national guidance	169	July 2018
Everolimus 0.25mg, 0.5mg and 0.75mg tablets (Certican®) SMC No 1288/17	Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogenic renal transplant	Not available as not recommended for use in NHS Scotland	165	Jan 2018
Everolimus (Certican®) (1117/15)	Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a cardiac transplant. Prophylaxis of organ rejection in patients receiving a hepatic transplant.	Not recommended	152	Nov/Dec 2015
Everolimus (Afinitor®) (1215/17)	Treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.	Available in line with National Guidance	160	Apr 2017
Everolimus (Afinitor®) (872/13)	For the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.	Not routinely available as local clinical experts do not with to add the medicine to the formulary at this time or there is a local preference for alternative medicines	129 152 155	Aug/Sept 2013 Nov/Dec 2015 June 2016
Everolimus (Votubia®) (884/13)	Renal angiomyolipoma associated with TSC	Not recommended	128	June/July 2013
Everolimus (Votubia®) (787/12)	Patients aged 3 years and older with SEGA	Not recommended	117	May/June

				2012
Everolimus (Afinitor®) (777/12)	Unresectable or metastatic, well or moderately-differentiated neuro-endocrine tumours of pancreatic origin	Non-formulary - pending protocol update	118 117	July 2012 May/June 2012
Everolimus (Afomotpr®) (595/10)	Advanced renal cell carcinoma on or after treatment with VEGF targeted therapy	Non-formulary - absence of clinician demand	143 96	Nov 2014 Apr/May 2010
Evolocumab (Repatha® PFS) (1148/16)	In adults with primary hypercholesterolaemia (heterozygous familial hypercholesterolaemia and non-familial) or mixed dyslipidaemia, as an adjunct to diet.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	156 160	Sep 2016 Apr 2017
Exagamglogene autotemcel dispersion for infusion (Casgevy®) Vertex Pharmaceuticals (Europe) Ltd SMC2709	For the treatment of transfusion-dependent beta-thalassemia in patients 12 years of age and older for whom haematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related haematopoietic stem cell donor is not available.			
Exemestane (Aromasin®) (210/05)	HR +ve early invasive breast cancer after 2-3 years of initial tamoxifen	GPs may prescribe under the direction of the Oncology clinic	108 Protocol 54	Aug 2011 2005
Exenatide solution for injection (Byetta®) (785/12)	Adjunctive therapy to basal insulin with or without metformin and/or pioglitazone in adults with type 2 diabetes	Non-formulary - GPs may prescribe under the direction of the Diabetes Clinic for existing patients	130 119 118	Sept/Oct 2013 Aug/Sept 2012 July 2012
Exenatide prolonged release injection (Bydureon®) (748/11)	Type 2 diabetes mellitus	Non-formulary - GPs may prescribe under the direction of the diabetes clinic for existing patients	130 116 114	Sept/Oct 2013 Apr/May 2012 Feb 2012

Exenatide injection (Byetta®) (684/11)	Type 2 diabetes mellitus	Non-formulary - restricted use for existing patients	130 104 101 Protocol with insulin 98 81 Protocol 71 Further info	Sept/Oct 2013 Mar 2011 Dec 10/Jan 2011 Aug/Sept 2010 July 2008 July 2007
Extended release epidural morphine (Depodur®) (528/09)	Post-operative pain following major orthopaedic, abdominal or pelvic surgery	Not recommended	95 86	Feb/Mar 2010 Jan 2009
Ex vivo expanded autologous human corneal epithelial cells containing stem cells (Holoclar®) SMC2261	Treatment of adult patients with moderate to severe limbal stem cell deficiency (defined by the presence of superficial corneal neovascularisation in at least two corneal quadrants, with central corneal involvement, and severely impaired visual acuity), unilateral or bilateral, due to physical or chemical ocular burns. In a retrospective uncontrolled case series study, HoloclarÒ was associated with transplant success in the majority of patients with limbal stem cell deficiency due to chemical or physical ocular burns	Available from a specialist centre in another NHS Board	181	November 2020
Ezetimibe/simvastatin (Inegy®)	Hypercholesterolaenia		109 89 52	2011 2009 2005
Ezetimibe (Ezetrol®)	Hypercholesterolaenia	Restricted use	31	2003

Updated: 13th May 2025

Back to top Back to homepage